Elizabeth M. Jaffee

56.0k total citations · 13 hit papers
386 papers, 30.7k citations indexed

About

Elizabeth M. Jaffee is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Elizabeth M. Jaffee has authored 386 papers receiving a total of 30.7k indexed citations (citations by other indexed papers that have themselves been cited), including 276 papers in Oncology, 207 papers in Immunology and 97 papers in Molecular Biology. Recurrent topics in Elizabeth M. Jaffee's work include Immunotherapy and Immune Responses (169 papers), Cancer Immunotherapy and Biomarkers (156 papers) and Pancreatic and Hepatic Oncology Research (98 papers). Elizabeth M. Jaffee is often cited by papers focused on Immunotherapy and Immune Responses (169 papers), Cancer Immunotherapy and Biomarkers (156 papers) and Pancreatic and Hepatic Oncology Research (98 papers). Elizabeth M. Jaffee collaborates with scholars based in United States, Germany and China. Elizabeth M. Jaffee's co-authors include Drew M. Pardoll, Mark Yarchoan, Lei Zheng, Daniel A. Laheru, Paul T. Golumbek, Eric R. Lutz, Leisha A. Emens, Todd D. Armstrong, Dung T. Le and Won Jin Ho and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Elizabeth M. Jaffee

379 papers receiving 30.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 2.3k citations Elizabeth M. Jaffee, Drew M. Pardoll et al. profile →
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

2018 1.8k citations Mark Yarchoan, Elizabeth M. Jaffee et al. profile →
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens

1994 980 citations Elizabeth M. Jaffee, Drew M. Pardoll et al. profile →
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

1999 945 citations Elizabeth M. Jaffee et al. profile →
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

2020 801 citations Won Jin Ho, Elizabeth M. Jaffee et al. profile →
Targeting neoantigens to augment antitumour immunity

2017 727 citations Mark Yarchoan, Eric R. Lutz et al. profile →
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

2009 565 citations Elizabeth M. Jaffee, Alison P. Klein et al. profile →
Mechanisms of Immune Evasion by Tumors

2006 545 citations Elizabeth M. Jaffee, Drew M. Pardoll et al. profile →
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

2022 468 citations Elizabeth M. Jaffee et al. profile →
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

2015 415 citations Lanqing Huang, Sara Solt et al. Cancer Immunology Research profile →
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

2019 386 citations Mark Yarchoan, Teena Vithayathil et al. profile →
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

2024 111 citations Mark Yarchoan, Elana J. Fertig et al. profile →
Recent advances in therapeutic cancer vaccines

2025 19 citations Elizabeth M. Jaffee, Mark Yarchoan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth M. Jaffee United States	89	18.4k	15.8k	9.3k	4.0k	3.9k	386	30.7k
George Coukos United States	87	17.6k 1.0×	17.1k 1.1×	13.0k 1.4×	5.4k 1.3×	2.9k 0.8×	396	35.5k
Steven Μ. Albelda United States	96	13.2k 0.7×	13.6k 0.9×	10.6k 1.1×	2.8k 0.7×	5.2k 1.4×	315	35.5k
Thomas F. Gajewski United States	82	19.8k 1.1×	20.9k 1.3×	11.9k 1.3×	2.5k 0.6×	3.1k 0.8×	321	36.1k
Ignacio Melero Spain	88	15.8k 0.9×	16.8k 1.1×	6.6k 0.7×	2.4k 0.6×	3.0k 0.8×	396	28.2k
Ton N. Schumacher Netherlands	83	17.9k 1.0×	22.7k 1.4×	9.7k 1.0×	2.5k 0.6×	2.4k 0.6×	311	34.3k
Robert H. Vonderheide United States	74	15.2k 0.8×	14.2k 0.9×	6.9k 0.7×	3.2k 0.8×	2.4k 0.6×	224	25.0k
Weiping Zou United States	79	16.9k 0.9×	19.8k 1.3×	10.9k 1.2×	5.0k 1.3×	4.1k 1.1×	188	35.3k
Francesco M. Marincola United States	84	12.2k 0.7×	15.3k 1.0×	9.5k 1.0×	2.8k 0.7×	1.6k 0.4×	491	27.7k
Suzanne L. Topalian United States	82	32.6k 1.8×	27.0k 1.7×	12.4k 1.3×	4.0k 1.0×	7.7k 2.0×	215	49.2k
Richard M. Sherry United States	51	18.5k 1.0×	13.8k 0.9×	6.1k 0.7×	1.7k 0.4×	2.8k 0.7×	97	25.0k

Countries citing papers authored by Elizabeth M. Jaffee

Since Specialization

Citations

This map shows the geographic impact of Elizabeth M. Jaffee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth M. Jaffee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth M. Jaffee more than expected).

Fields of papers citing papers by Elizabeth M. Jaffee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth M. Jaffee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth M. Jaffee. The network helps show where Elizabeth M. Jaffee may publish in the future.

Co-authorship network of co-authors of Elizabeth M. Jaffee

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth M. Jaffee. A scholar is included among the top collaborators of Elizabeth M. Jaffee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth M. Jaffee. Elizabeth M. Jaffee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hill, Colin, Rose Parkinson, Elizabeth M. Jaffee, et al.. (2024). Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics. 121(4). 930–941. 5 indexed citations

Bayless, Nicholas, Jeffrey A. Bluestone, Samantha Bucktrout, et al.. (2021). Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. Journal for ImmunoTherapy of Cancer. 9(9). e002627–e002627. 19 indexed citations

Davis-Marcisak, Emily F., Atul Deshpande, Genevieve Stein-O’Brien, et al.. (2021). From bench to bedside: Single-cell analysis for cancer immunotherapy. Cancer Cell. 39(8). 1062–1080. 64 indexed citations

Osipov, Arsen, Su Jin Lim, Aleksandra Popović, et al.. (2020). Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. Clinical Cancer Research. 26(18). 4842–4851. 69 indexed citations

Ribas, Antoni, Rajarshi Sengupta, Sayyed K. Zaidi, et al.. (2020). Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discovery. 11(2). 233–236. 132 indexed citations

Nair, Nitya, Ed Lemmens, Serena Chang, et al.. (2020). Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer. Cancer Immunology Research. 8(5). 609–617. 17 indexed citations

Surcel, Alexandra, Eric S. Schiffhauer, Dustin Thomas, et al.. (2019). Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14. Cancer Research. 79(18). 4665–4678. 51 indexed citations

Hassan, Raffit, Evan Alley, Hedy L. Kindler, et al.. (2019). Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research. 25(19). 5787–5798. 88 indexed citations

Danilova, Ludmila, Won Jin Ho, Qingfeng Zhu, et al.. (2019). Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunology Research. 7(6). 886–895. 180 indexed citations

10.

Stein, Julie E., Evan J. Lipson, Tricia R. Cottrell, et al.. (2019). Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research. 26(3). 545–551. 92 indexed citations

11.

Kim, Amy K., Faiz Gani, Andrew J. Layman, et al.. (2019). Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research. 7(5). 805–812. 20 indexed citations

12.

Foote, Jeremy B., Marleen Kok, James M. Leatherman, et al.. (2017). A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunology Research. 5(6). 468–479. 117 indexed citations

13.

Rucki, Agnieszka A., Qian Xiao, Stephen Muth, et al.. (2017). Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Molecular Cancer Therapeutics. 16(11). 2399–2409. 28 indexed citations

14.

Kim, Min‐Sik, Elizabeth D. Thompson, Lanqing Huang, et al.. (2016). Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunology Research. 4(3). 225–233. 19 indexed citations

15.

Wang, Qingfei, Shau-Hsuan Li, Hai Wang, et al.. (2012). Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. Cancer Research. 72(17). 4417–4428. 33 indexed citations

16.

Uram, Jennifer N., et al.. (2011). Nondominant CD8 T Cells Are Active Players in the Vaccine-Induced Antitumor Immune Response. The Journal of Immunology. 186(7). 3847–3857. 15 indexed citations

17.

Kim, Peter, Todd D. Armstrong, Hong Song, et al.. (2008). Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. Journal of Clinical Investigation. 118(5). 1700–1711. 66 indexed citations

18.

Laheru, Dan, Eric R. Lutz, James M. Burke, et al.. (2008). Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research. 14(5). 1455–1463. 259 indexed citations

19.

Singh, Reshma, et al.. (2005). Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse. The Journal of Immunology. 175(6). 3663–3673. 88 indexed citations

20.

Wolpoe, Matthew E., Eric R. Lutz, Anne M. Ercolini, et al.. (2003). HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/ neu -Transgenic Mice. The Journal of Immunology. 171(4). 2161–2169. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact